Matthew W. Martin
Department of Medicinal Chemistry
Amgen Inc.
One Kendall Square
Cambridge
USA
Name/email consistency: high
- Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin, M.W., Newcomb, J., Nunes, J.J., Boucher, C., Chai, L., Epstein, L.F., Faust, T., Flores, S., Gallant, P., Gore, A., Gu, Y., Hsieh, F., Huang, X., Kim, J.L., Middleton, S., Morgenstern, K., Oliveira-dos-Santos, A., Patel, V.F., Powers, D., Rose, P., Tudor, Y., Turci, S.M., Welcher, A.A., Zack, D., Zhao, H., Zhu, L., Zhu, X., Ghiron, C., Ermann, M., Johnston, D., Saluste, C.G. J. Med. Chem. (2008)
- Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties. Martin, M.W., Newcomb, J., Nunes, J.J., Bemis, J.E., McGowan, D.C., White, R.D., Buchanan, J.L., DiMauro, E.F., Boucher, C., Faust, T., Hsieh, F., Huang, X., Lee, J.H., Schneider, S., Turci, S.M., Zhu, X. Bioorg. Med. Chem. Lett. (2007)
- Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. Martin, M.W., Newcomb, J., Nunes, J.J., McGowan, D.C., Armistead, D.M., Boucher, C., Buchanan, J.L., Buckner, W., Chai, L., Elbaum, D., Epstein, L.F., Faust, T., Flynn, S., Gallant, P., Gore, A., Gu, Y., Hsieh, F., Huang, X., Lee, J.H., Metz, D., Middleton, S., Mohn, D., Morgenstern, K., Morrison, M.J., Novak, P.M., Oliveira-dos-Santos, A., Powers, D., Rose, P., Schneider, S., Sell, S., Tudor, Y., Turci, S.M., Welcher, A.A., White, R.D., Zack, D., Zhao, H., Zhu, L., Zhu, X., Ghiron, C., Amouzegh, P., Ermann, M., Jenkins, J., Johnston, D., Napier, S., Power, E. J. Med. Chem. (2006)
